SYNKLINO
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
SYNKLINO
Social Links:
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Lyngby, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.synklino.com
Total Employee:
1+
Status:
Active
Contact:
+45 20 12 16 56
Email Addresses:
[email protected]
Total Funding:
232 M DKK
Technology used in webpage:
Team.blue
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Nanostics
Nanostics is a developer of diagnostics tests intended to diagnose aggressive prostate cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
EIR Ventures
EIR Ventures investment in Series A - Synklino
PKA
PKA investment in Series A - Synklino
Maj Invest Equity
Maj Invest Equity investment in Series A - Synklino
Vaekstfonden
Vaekstfonden investment in Series A - Synklino
Vaekstfonden
Vaekstfonden investment in Seed Round - Synklino
EIR Ventures
EIR Ventures investment in Seed Round - Synklino
BioInnovation Institute
BioInnovation Institute investment in Convertible Note - Synklino
Official Site Inspections
http://www.synklino.com Semrush global rank: 5.02 M Semrush visits lastest month: 1.64 K
- Host name: linux12.scannet.dk
- IP address: 185.21.43.12
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Synklino"
About - Synklino
Synklino is building a diverse team with different and complementary skills, experiences, genders, ages, nationalities, and cultural backgrounds. This is what makes Synklino strong. 87%. Share of organisation with Annual R&D spend …See details»
Synklino - Crunchbase Company Profile & Funding
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic …See details»
Synklino Company Profile | Management and Employees List
Synklino is a Danish biotech company developing groundbreaking therapies against cytomegalovirus (CMV), a devastating virus infection. It is a spin-out from the University of …See details»
Investors - Synklino
May 22, 2024 Investment in First-in-Class anti-viral drug development Synklino is a Danish biotech company developing groundbreaking therapies for treatment of patients with chronic …See details»
Synklino - Org Chart, Teams, Culture & Jobs - The Org
View Synklino's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Synklino Company Profile 2024: Valuation, Funding & Investors
Synklino General Information Description. Developer of a CMV-specific immunotoxin designed to eradicate cytomegalovirus infection. The company offers to provide rapid relief from the …See details»
Synklino - Company Profile - Tracxn
Nov 27, 2024 Synklino - Developer of drugs for the treatment of chronic viral infections. Raised a total funding of $32.3M over 5 rounds from 10 investors. Valued at $10.1M. Founded by …See details»
Synklino ApS - life-sciences-europe.com
Jul 7, 2017 Synklino is a Danish biotech company developing groundbreaking therapies against cytomegalovirus (CMV), a devastating virus infection. It is a spin-out from the University of …See details»
Synklino Company Profile - Office Locations, Competitors ... - Craft
Synklino is a company providing long-term survival for transplant recipients by offering a solution for the eradication of cytomegalovirus (CMV) infections. Its drug candidate SYNx is a fast …See details»
Synklino - Products, Competitors, Financials, Employees, …
Synklino's therapies are intended for the healthcare sector, with a particular focus on improving outcomes for organ and stem cell transplant recipients. It was founded in 2017 and is based in …See details»
Synklino - Funding, Financials, Valuation & Investors - Crunchbase
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much funding has …See details»
Annual Report 2022 - Synklino
Synklino at a glance 159 mDKK 100,000 100 years 87% 45 mDKK SYN002 1 2 Cash and bonds as of 31 December 2022 Two-pronged product strategy Management’s life science Synklino is …See details»
Synklino Company Information - Funding, Investors, and More
The company Synklino has raised a total of $33.38m in funding over 2 rounds. Key Insights: Series A: $31.9m; Unknown: $1.48m; 2019. Synklino Unknown (2019, $1M) $1.48m. 2022. …See details»
SYN-002 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 —Synklino, a biotech company developing treatments for chronic viral infections, closed a €29.8 million (about $31.9 million) Series A funding round. The Copenhagen, …See details»
Synklino - VentureRadar
Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV) Source: prnewswire.co.uk. BIO-Europe …See details»
Annual Report 2023 - Synklino
Synklino by visiting synklino.com Business and strategy CMV – the disease and target groups 12 SYN002 – First-in-class drug candidate 14 Recent progress and the way forward for SYN002 …See details»
Synklino - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Synklino . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of Board …See details»
Synklino - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Synklino . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 3. Monthly Visits 128. …See details»
Career - Synklino
Join us Come join Synklino’s team and our work to develop first in class antiviral pharmceuticals – starting with CMV infection in immunocompromized patients View current job openings See …See details»